A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to: a) evaluate the tolerability and safety of the
co-administration of Fluzoparib and mFOLFIRINOX followed by Fluzoparib Maintenance
Monotherapy in patients with advanced pancreatic cancer, and establish the maximum tolerated
dose and recommended phase II dose of the combination; and b) assess the efficacy of the
co-administration of Fluzoparib and mFOLFIRINOX followed by Fluzoparib Maintenance
Monotherapy in patients with advanced pancreatic cancer.